Angiogenesis in health and disease

Nature Medicine

Volumn 9, Issue 6, 2003, Pages 653-660

  Carmeliet, Peter ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN 1; CD31 ANTIGEN; CHEMOKINE; CYTOKINE; GROWTH FACTOR; NOTCH RECEPTOR; OCCLUDIN; PLATELET DERIVED GROWTH FACTOR BB; PROTEINASE; SERINE PROTEINASE INHIBITOR; THROMBOSPONDIN; VASCULOTROPIN;

ANGIOGENESIS; BLOOD CLOTTING; CANCER CHEMOTHERAPY; CELL FATE; ENDOTHELIUM CELL; ENZYME DEGRADATION; EXTRACELLULAR MATRIX; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOPATHOLOGY; INFECTION; INFLAMMATION; ISCHEMIA; LEUKOCYTE; PHYSICAL DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SMOOTH MUSCLE FIBER; STEM CELL; VASCULAR ENDOTHELIUM;

ANIMALS; BLOOD COAGULATION; BLOOD VESSELS; HUMANS; LEUKOCYTES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; SIGNAL TRANSDUCTION; STEM CELLS;

EID: 0037699955     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0603-653     Document Type: Review

References (132)

1. Luttun, A., Carmeliet, G. & Carmeliet, P. Vascular progenitors: from biology to treatment. Trends Cardiovasc. Med., 12, 88-96 (2002).
2. Rafii, S., Lyden, D., Benezra, R., Hattori, K. & Heissig, B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer 2, 826-835 (2002).
3. Asahara, T. & Isner, J.M. Endothelial progenitor cells for vascular regeneration. J. Hematother. Stem Cell Res. 11, 171-178 (2002).
4. Mikkola, H.K. & Orkin, S.H. The search for the hemangioblast. J. Hematother. Stem Cell Res, 11, 9-17 (2002).
5. Reyes, M. et al. Origin of endothelial progenitors in human postnatal bone marrow. J. Clin. Invest. 109, 337-346 (2002).
6. Rehman, J., Li, J., Orschell, C.M. & March, K.L. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107, 1164-1169 (2003).
7. Takakura, N. et al. A role for hematopoietic stem cells in promoting angiogenesis. Cell 102, 199-209 (2000).
8. Grant, M.B. et al. Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat. Med. 8, 607-612 (2002).
9. Gerber, H.R et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417, 954-958 (2002).
10. + stem cells from bone-marrow microenvironment. Nat. Med. 8, 841-849 (2002).
11. Lyden, D. et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7, 1194-1201 (2001).
12. Luttun, A. et al. Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. 8, 831-840 (2002).
13. Rafii, S. & Lyden, D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. 9, 702-712 (2003).
14. Carmeliet, P. Developmental biology. One cell, two fates. Nature 408, 43-45 (2000).
15. Lawson, N.D. et al. Notch signaling is required for arterial-venous differentiation during embryonic vascular development. Development 128, 3675-3683 (2001).
16. Zhong, T.P., Childs, S., Leu, J.P. & Fishman, M.C. Gridlock signalling pathway fashions the first embryonic artery. Nature 414, 216-220 (2001).
17. Lawson, N.D., Vogel, A.M. & Weinstein, B.M. Sonic hedgehog and vascular endothelial growth factor act upstream of the Notch pathway during arterial endothelial differentiation. Dev. Cell 3, 127-136 (2002).
18. Stalmans, I. et al. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J. Clin. Invest. 109, 327-336 (2002).
19. Visconti, R.P., Richardson, C.D. & Sato, T.N. Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc. Natl. Acad. Sci. USA 99, 8219-8224 (2002).
20. Kalimo, H., Ruchoux, M.M., Viitanen, M. & Kalaria, R.N. CADASIL: a common form of hereditary arteriopathy causing brain infarcts and dementia. Brain Pathol. 12, 371-384 (2002).
21. Mukouyama, Y.S., Shin, D., Britsch, S., Taniguchi, M. & Anderson, D.J. Sensory nerves determine the pattern of arterial differentiation and blood vessel branching in the skin. Cell 109, 693-705 (2002).
22. Cleaver, O. & Melton, D.A. Endothelial signaling during development. Nat. Med. 9, '-' (2003).
23. Jain, R.K. & Munn, L.L. Leaky vessels? Call Ang1! Nat. Med. 6, 131-132 (2000).
24. Suri, C. et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 282, 468-471 (1998).
25. LeCouter, J. et al. Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 412, 877-884 (2001).
26. Ruoslahti, E. Drug targeting to specific vascular sites. Drug Discov. Today 7, 1138-1143 (2002).
27. Sood, A.K., Fletcher, M.S. & Hendrix, M.J. The embryonic-like properties of aggressive human tumor cells. J. Soc. Gynecol. Investig. 9, 2-9 (2002).
28. Wang, H.U., Chen, Z.F. & Anderson, D.J. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor EphB4. Cell 93, 741-753 (1998).
29. Gerety, S.S., Wang, H.U., Chen, Z.F. & Anderson, D.J. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol. Cell 4, 403-414 (1999).
30. Zhang, X.Q. et al. Stromal cells expressing ephrin-B2 promote the growth and sprouting of ephrin-B2(+) endothelial cells. Blood 98, 1028-1037 (2001).
31. Gale, N.W. et al. Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. Dev. Biol. 230, 151-160 (2001).
32. Shin, D. et al. Expression of ephrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularization. Dev. Biol. 230, 139-150 (2001).
33. Stalmans, I. et al. VEGF: A modifier of the del22q11 (DiGeorge) syndrome? Nat. Med. 9, 173-182 (2003).
34. Loughna, S. & Sato, T.N. A combinatorial role of angiopoietin-1 and orphan receptor TIE1 pathways in establishing vascular polarity during angiogenesis. Mol. Cell 7, 233-239 (2001).
35. Pugh, C.W. & Ratcliffe, P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 9, 677-684 (2003).
36. Ferrara, N., Gerber, H.-P., LeCouter, J. & Lin, R. The biology of VEGF and its receptors. Nat. Med. 9, 669-676 (2003).
37. Carmeliet, P. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439 (1996).
38. Ferrara, N. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439-442 (1996).
39. Oosthuyse, B. et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 28, 131-138 (2001).
40. Carmeliet, P. et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7, 575-583 (2001).
41. Carmeliet, P. et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98, 147-157 (1999).
42. Corada, M. et al. A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood 100, 905-911 (2002).
43. Thurston, G. et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat. Med. 6, 460-463 (2000).
44. Simon, A.M. & McWhorter, A.R. Vascular abnormalities in mice lacking the endothelial gap junction proteins connexin37 and connexin40. Dev. Biol. 251, 206-220 (2002).
45. Hangai, M. et al. Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. Am. J. Pathol.161, 1429-1437 (2002).
46. Hynes, R.O. A reevaluation of integrins as regulators of angiogenesis. Nat. Med. 8, 918-921 (2002).
47. Hood, J.D. & Cheresh, D.A. Role of integrins in cell invasion and migration. Nat. Rev. Cancer 2, 91-100 (2002).
48. Pepper, M.S. Extracellular proteolysis and angiogenesis. Thromb. Haemost. 86, 346-355 (2001).
49. Jackson, C. Matrix metalloproteinases and angiogenesis. Curr. Opin. Nephrol. Hypertens. 11, 295-299 (2002).
50. Luttun, A., Dewerchin, M., Collen, D. & Carmeliet, P. The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies. Curr. Atheroscler. Rep. 2, 407-416 (2000).
51. Qi, J.H. et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat. Med. 9, 407-415 (2003).
52. Blasi, F. & Carmeliet, P. uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell Biol. 3, 932-943 (2002).
53. Bajou, K. et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 4, 923-928 (1998).
54. Jain, R.K. Molecular regulation of vessel maturation. Nat. Med. 9, 685-693 (2003).
55. Hellstrom, M. et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J. Cell Biol. 153, 543-553 (2001).
56. Abramsson, A. et al. Analysis of mural cell recruitment to tumor vessels. Circulation 105, 112-117 (2002).
57. Dinehart, S.M., Kincannon, J. & Geronemus, R. Hemangiomas: evaluation and treatment. Dermatol. Surg. 27, 475-485 (2001).
58. Richardson, T.P., Peters, M.C., Ennett, A.B. & Mooney, D.J. Polymeric system for dual growth factor delivery. Nat. Biotechnol. 19, 1029-1034 (2001).
59. Cao, R. et al. Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-αα and -αβ receptors. FASEB J. 16, 1575-1583 (2002).
60. Takagi, H. et al. Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization. Invest. Ophthal. Mol. Vis. Sci. 44, 393-402. (2003).
61. Shim, W.S. et al. Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. Exp. Cell Res. 279, 299-309 (2002).
62. Hattori, K. et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J. Exp. Med. 193, 1005-1014 (2001).
63. Ahmad, S.A. et al. The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res. 61, 1255-1259 (2001).
64. Carlson, T.R., Feng, Y., Maisonpierre, P.C., Mrksich, M. & Morla, A.O. Direct cell adhesion to the angiopoietins mediated by integrins. J. Biol. Chem. 276, 26516-26525 (2001).
65. Gale, N.W. et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev. Cell 3, 411-23 (2002).
66. Maisonpierre, P.C. et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277, 55-60 (1997).
67. Hackett, S.F., Wiegand, S., Yancopoulos, G. & Campochiaro, P.A. Angiopoietin-2 plays an important role in retinal angiogenesis. J. Cell. Physiol. 192, 182-187 (2002).
68. Vikkula, M. et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 87, 1181-1190 (1996).
69. van den Driesche, S., Mummery, C.L. & Westermann, C.J. Hereditary hemorrhagic telangiectasia: an update on transforming growth factor β signaling in vasculogenesis and angiogenesis. Cardiovasc. Res. 58, 20-31 (2003).
70. Lamouille, S., Mallet, C., Feige, J.J. & Bailly, S. Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis. Blood 100, 4495-4501 (2002).
71. Goumans, M.J. et al. Balancing the activation state of the endothelium via two distinct TGF-β type I receptors. EMBO J. 21, 1743-1753 (2002).
72. Srinivasan, S. et al. A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum. Mol. Genet. 12, 473-482 (2003).
73. Humbert, M. & Trembath, R.C. Genetics of pulmonary hypertension: from bench to bedside. Eur. Respir. J. 20, 741-749 (2002).
74. Du, L. et al. Signaling molecules in nonfamilial pulmonary hypertension. N. Engl. J. Med. 348, 500-509 (2003).
75. Voelkel, N.F. et al. Janus face of vascular endothelial growth factor: the obligatory survival factor for lung vascular endothelium controls precapillary artery remodeling in severe pulmonary hypertension. Crit. Care Med. 30, S251-S256 (2002).
76. Yeager, M.E., Halley, G.R., Golpon, H.A., Voelkel, N.F & Tuder, R.M. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ. Res. 88, E2-E11 (2001).
77. Helisch, A. & Schaper, W. Arteriogenesis: the development and growth of collateral arteries. Microcirculation 10, 83-97 (2003).
78. Kamihata, H. et al. Improvement of collateral perfusion and regional function by implantation of peripheral blood mononuclear cells into ischemic hibernating myocardium. Arterioscler. Thromb. Vasc. Biol. 22, 1804-1810 (2002).
79. Heil, M. et al. Blood monocyte concentration is critical for enhancement of collateral artery growth. Am. J. Physiol. Heart Circ. Physiol. 283, H2411-H2419 (2002).
80. van Royen, N. et al. Exogenous application of transforming growth factor β1 stimulates arteriogenesis in the peripheral circulation. FASEB J. 16, 432-434 (2002).
81. Buschmann, I.R. et al. GM-CSF: a strong arteriogenic factor acting by amplification of monocyte function. Atherosclerosis 159, 343-356 (2001).
82. Voskuil, M. et al. Modulation of collateral artery growth in a porcine hindlimb ligation model using MCP-1. Am. J. Physiol. Heart Circ. Physiol. 284, H1422-H1428 (2003).
83. Hoefer, I.E. et al. Direct evidence for tumor necrosis factor-α signaling in arteriogenesis. Circulation 105, 1639-1641 (2002).
84. Pipp, F. et al. VEGFR-1-selective VEGF homologue PIGF is arteriogenic: evidence for a monocyte-mediated mechanism. Circ. Res. 92, 378-385 (2003).
85. Cao, R. et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat. Med. (2003).
86. Isner, J.M. Myocardial gene therapy. Nature 415, 234-239 (2002).
87. Vacca, A. et al. Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis. Int. J. Clin. Lab. Res. 28, 55-68 (1998).
88. Norrby, K. Mast cells and angiogenesis. APMIS 110, 355-371 (2002).
89. Li, X.F. et al. Angiogenic growth factor messenger ribonucleic acids in uterine natural killer cells. J. Clin. Endocrinol. Metab. 86, 1823-1834 (2001).
90. Sica, A., Saccani, A. & Mantovani, A. Tumor-associated macrophages: a molecular perspective. Int. Immunopharmacol. 2, 1045-1054 (2002).
91. Coussens, L.M. et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 13, 1382-1397 (1999).
92. Banchereau, J. & Steinman, R.M. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
93. Schmeisser, A. & Strasser, R.H. Phenotypic overlap between hematopoietic cells with suggested angioblastic potential and vascular endothelial cells. J. Hematother. Stem Cell Res. 11, 69-79 (2002).
94. Nykanen, A.I. et al. Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation 107, 1308-1314 (2003).
95. Melder, R.J. et al. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat. Med. 2, 992-997 (1996).
96. Carbone, J.E. & Ohm, D.P. Immune dysfunction in cancer patients. Oncology (Huntington) 16, 11-18 (2002).
97. Dermond, O. & Ruegg, C. Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs: emerging mechanisms and therapeutic perspectives. Drug Resist. Update 4, 314-321 (2001).
98. Bernardini, G. et al. Analysis of the role of chemokines in angiogenesis. J. Immunol. Meth. 273, 83-101 (2003).
99. Trikha, M. & Nakada, M.T. Platelets and cancer: implications for antiangiogenic therapy. Semin. Thromb. Hemost. 28, 39-44 (2002).
100. Carmeliet, P. Biomedicine. Clotting factors build blood vessels. Science 293, 1602-1604 (2001).
101. Fernandez, P.M. & Rickles, F.R. Tissue factor and angiogenesis in cancer. Curr. Opin. Hematol. 9, 401-406 (2002).
102. English, D., Brindley, D.N., Spiegel, S. & Garcia, J.G. Lipid mediators of angiogenesis and the signalling pathways they initiate. Biochim. Biophys. Acta 1582, 228-239 (2002).
103. Benjamin, L.E., Golijanin, D., Itin, A., Pode, D. & Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103, 159-165 (1999).
104. Dor, Y. et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J. 21, 1939-1947 (2002).
105. Boudier, H.A. Arteriolar and capillary remodelling in hypertension. Drugs 58 (suppl. 1), 37-40 (1999).
106. Benjamin, L.E., Hemo, I. & Keshet, E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125, 1591-1598 (1998).
107. Vailhe, B. & Feige, J.J. Thrombospondins as anti-angiogenic therapeutic agents. Curr. Pharm. Des. 9, 583-588 (2003).
108. Holash, J. et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284, 1994-1998 (1999).
109. Schonfeld, C.L. Hyalocytes inhibit retinal pigment epithelium cell proliferation in vitro. Ger. J. Ophthalmol. 5, 224-228 (1996).
110. Makino, Y., Kanopka, A., Wilson, W.J., Tanaka, H. & Poellinger, L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3α locus. J. Biol. Chem. 277, 32405-32408 (2002).
111. D'Amore, P.A. & Ng, Y.S. Tales of the cryptic: unveiling more angiogenesis inhibitors. Trends Mol. Med. 8, 313-315 (2002).
112. Meyer, M. et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGFE, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt1) receptor tyrosine kinases. EMBO J. 18, 363-374 (1999).
113. Harada, K., Lu, S., Chisholm, D.M., Syrjanen, S. & Schor, A.M. Angiogenesis and vasodilation in skin warts. Association with HPV infection. Anticancer Res. 20, 4519-4523 (2000).
114. Barillari, G. & Ensoli, B. Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma. Clin. Microbiol. Rev. 15, 310-326 (2002).
115. Rupnick, M.A. et al. Adipose tissue mass can be regulated through the vasculature. Proc. Natl. Acad. Sci. USA 99, 10730-10735 (2002).
116. Hackett, S.F. et al. Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. J. Cell Physiol. 184, 275-284 (2000).
117. De La Torre, J.C. Alzheimer's disease: How does it start? J. Alzheimers Dis. 4, 497-512 (2002).
118. Krupinski, J., Kaluza, J., Kumar, P., Kumar, S. & Wang, J.M. Role of angiogenesis in patients with cerebral ischemic stroke. Stroke 25, 1794-1798 (1994).
119. Van Belle, E. et al. Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. Circulation 96, 2667-2674 (1997).
120. Waltenberger, J. Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc. Res. 49, 554-560 (2001).
121. Rivard, A. et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am. J. Pathol. 154, 355-363 (1999).
122. Gennaro, G., Menard, C., Michaud, S.E. & Rivard, A. Age-dependent impairment of reendothelialization after arterial injury: role of vascular endothelial growth factor. Circulation 107, 230-233 (2003).
123. Jenkinson, L., Bardhan, K.D., Atherton, J. & Kalia, N. Helicobacter pylori prevents proliferative stage of angiogenesis in vitro: role of cytokines. Dig. Dis. Sci. 47, 1857-1862 (2002).
124. Yano, K., Brown, L.F. & Detmar, M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J. Clin. Invest. 107, 409-417 (2001).
125. Chang, E., Yang, J., Nagavarapu, U. & Herron, G.S. Aging and survival of cutaneous microvasculature. J. Invest. Dermatol. 118, 752-758 (2002).
126. Maynard, S.E. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649-658 (2003).
127. Hewett, P. et al. Down-regulation of angiopoietin-1 expression in menorrhagia. Am. J. Pathol. 160, 773-780 (2002).
128. Compernolle, V. et al. Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat. Med. 8, 702-710 (2002).
129. Kasahara, Y. et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J. Clin. Invest. 106, 1311-1319 (2000).
130. Kang, D.H. et al. Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease. Am. J. Kidney Dis. 37, 601-611 (2001).
131. Martinez, P., Esbrit, P., Rodrigo, A., Alvarez-Arroyo, M.V. & Martinez, M.E. Age-related changes in parathyroid hormone-related protein and vascular endothelial growth factor in human osteoblastic cells. Osteoporos. Int. 13, 874-881 (2002).
132. Yin, G. et al. Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis. Mol. Ther. 5, 547-554 (2002).